Skip to Content

Zanaflex (tizanidine) Disease Interactions

There are 4 disease interactions with Zanaflex (tizanidine):

Major

Tizanidine (Includes Zanaflex) ↔ Hepatotoxicity

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Tizanidine may cause hepatocellular injury. According to the manufacturer, approximately 5% of patients treated with tizanidine in clinical studies had elevations in serum transaminases greater than 3 times the upper limit of normal (or 2 times if baseline levels were elevated), compared to 0.4% in control patients. Most cases were asymptomatic and resolved rapidly following withdrawal of the drug. However, liver failure resulting in death has been reported in postmarketing use. In three cases cited by the package labeling, two involved concomitant use of hepatotoxic agents in addition to tizanidine, while the third had no other known risk factors. Because of potential hepatotoxicity, therapy with tizanidine should be administered cautiously in patients with impaired hepatic function. All patients treated with tizanidine should have liver function tests performed at baseline, 1, 3 and 6 months, and periodically thereafter. In addition, they should be instructed to immediately report any signs and symptoms of hepatic injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine and jaundice.

References

  1. Wallace JD "Summary of combined clinical analysis of controlled clinical trials with tizanidine." Neurology 44 (11 sup (1994): s60-8;dic. 68-9
  2. "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.
  3. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A "Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group." Neurology 44 (11 sup (1994): s44-51;dic. 51-2
View all 4 references
Major

Tizanidine (Includes Zanaflex) ↔ Hypotension

Severe Potential Hazard, High plausibility

Applies to: Hypotension, Dehydration

Tizanidine is a centrally-acting alpha-2 adrenergic agonist with 1/10 to 1/50 the potency of clonidine in lowering blood pressure. According to the manufacturer, two-thirds of patients in a study given single 8 mg doses of tizanidine had a 20% reduction in either the diastolic or systolic blood pressure. The effect was seen one hour after dosing and peaked at 2 to 3 hours post-dose. Bradycardia, orthostatic hypotension, lightheadedness, dizziness and, rarely, syncope have occurred. Therapy with tizanidine should be administered cautiously in patients with or predisposed to hypotension. The risk of significant hypotension may be minimized by gradual dosage titration. Patients should be advised not to rise abruptly from a supine position.

References

  1. Wallace JD "Summary of combined clinical analysis of controlled clinical trials with tizanidine." Neurology 44 (11 sup (1994): s60-8;dic. 68-9
  2. "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.
Major

Tizanidine (Includes Zanaflex) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

The clearance of tizanidine has been shown to reduce by more than 50% in elderly patients with renal impairment (creatinine clearance < 25 mL/min) compared to healthy elderly patients. Prolonged pharmacologic effects of tizanidine may occur due to drug accumulation. Therapy with tizanidine should be administered cautiously and initiated at reduced dosages in patients with impaired renal function. During titration, individual doses rather than the dosing frequency should be increased.

References

  1. "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.
Moderate

Tizanidine (Includes Zanaflex) ↔ Psychoses

Moderate Potential Hazard, Moderate plausibility

Applies to: Psychosis, History - Psychiatric Disorder

Formed, visual hallucinations or delusions have been reported in 3% of patients treated with tizanidine in two North American controlled clinical studies. Therapy with tizanidine should be administered cautiously in patients with a history of psychiatric disorders.

References

  1. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD "Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group." Neurology 44 (11 sup (1994): s34-42;dic. 42-3
  2. "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.
  3. Wallace JD "Summary of combined clinical analysis of controlled clinical trials with tizanidine." Neurology 44 (11 sup (1994): s60-8;dic. 68-9
View all 4 references

Zanaflex (tizanidine) drug Interactions

There are 978 drug interactions with Zanaflex (tizanidine)

Zanaflex (tizanidine) alcohol/food Interactions

There are 2 alcohol/food interactions with Zanaflex (tizanidine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide